Explore a Phase 2 clinical trial for Primary Central Nervous System Lymphoma (PCNSL). Learn about eligibility and enrollment details at EndBrainCancer.org.
Explore a Phase 2 clinical trial for Primary Central Nervous System Lymphoma (PCNSL). Learn about eligibility and enrollment details at EndBrainCancer.org.
Positron Emission Tomography (PET) is a powerful imaging technique that uses radioactive tracers called imaging agents.
Hear directly from Dr. John de Groot about TLX101-CDx, an agent for the imaging of gliomas.
CISCRP is looking for adult patients diagnosed with Glioblastoma and/or their caregivers to participate in an advisory board.
Advocate for the Promising Pathway Act (S. 4426). Share your story and its importance.
Discover brain cancer treatment options for 2025. Learn about clinical trials, personalized medicine, and patient advocacy from the End Brain Cancer Initiative.
You have the opportunity to make a difference by sharing your experience and insights related to Primary Central Nervous System Lymphoma (PCNSL)!
You have the opportunity to make a difference by sharing your experience and insights related to Primary Central Nervous System Lymphoma (PCNSL)!
A clinical trial of the CVGBM cancer vaccine showed positive T-cell responses in over 75% of glioblastoma patients.
Patient and care partner survey, your opportunity to share your experience and insights about Primary Central Nervous System Lymphoma (PCNSL).
Imvax Presents Early Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting.
Patient and care partner survey, your opportunity to share your experience and insights about Primary Central Nervous System Lymphoma (PCNSL).